The global trade tensions were enough to bring many stocks to their true valuations. But the good part was that it also helped in bringing high growth stocks to the fore.
REA Group Ltd (REA)
REA Group Ltd achieved strong financial performance for the half-year ending 31 December 2024. The core revenue rising 20% to $873 million and Operating expenses increased 18% to $338 million, while EBITDA excluding associates grew by 22% to $535 million. Net profit from core operations climbed 26% to $314 million, with earnings per share also up 26% to $2.38. Fully franked interim dividend of $1.10 per share was declared, a 26% increase. The reported net profit, including one-off gains such as the sale of its PropertyGuru asset, surged 246% to $441 million.
In Australia, revenue grew 19% to $809 million, with residential revenue up 21% to $614 million. Rent revenue also saw a boost, supported by higher pricing and listing volumes. Financial Services revenue grew 13%, driven by more loan submissions and settlements, along with a greater uptake of white label products. Commercial and Developer revenue rose 10%, with Commercial benefiting from stronger pricing and listings. Other revenue climbed 9%, led by strong performance from CampaignAgent, despite weaker results from PropTrack and programmatic display ads.
Internationally, REA India delivered a 46% increase in revenue to $64 million. Strong growth came from Housing Edge’s adjacent services, up 153%, and a 15% lift in Housing.com revenue, especially in Tier 2 cities.
The company, among the best growth stocks to buy now anticipates ongoing yield growth, moderated house price increases due to higher listing volumes, and lower expense growth in the second half of FY25. Investments in innovation and consumer experiences remain a priority.
Pro Medicus Limited (ASX: PME)
On 15 April 2025, Pro Medicus Limited (ASX: PME), through its US subsidiary Visage Imaging, has secured a multi-year research collaboration agreement with UCSF. This partnership will focus on advancing artificial intelligence (AI) in medical imaging using the Visage AI Accelerator platform. The agreement supports research and development efforts with a path to commercialisation and builds on an existing partnership for the Visage 7 Viewer. The platform is designed for clinical research by providing tools for data de-identification, curation, and analysis, enabling the integration of AI directly into clinical workflows, and improving outcomes through innovative healthcare solution.
In March 2025, the company signed a significant A$40 million, 7-year contract with LucidHealth, a major radiology service provider in the US. Under the deal, Visage 7 will replace LucidHealth’s legacy imaging systems, with a full cloud-based deployment using a transactional licensing model. This agreement expands Pro Medicus' footprint in North America's private teleradiology market. The solution will support both remote and on-site radiology services across LucidHealth’s 140 care sites and over 300 radiologists, further cementing Visage 7 as a leading platform for scalable, cloud-based diagnostic imaging.
PME is one of the top growth stocks and has declared a good financial performance for the half-year ending December 2024. Revenue rising 31.1% to $97.2 million and net profit increasing 42.7% to $51.7 million. The company maintains a debt-free position, with cash and financial assets totaling $182.3 million. Several high-value contracts were won or renewed, including deals worth $365 million with Trinity Health, Lurie Children’s Hospital, and Duly Health. Additional upgrades were secured with Duke Health and NYU Langone. Margins improved to 72% driven by a boost in transaction revenue. A fully franked interim dividend of 25c per share was declared, reflecting robust growth and confidence in future opportunities.
(Source: Company Announcements)
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
